Obesity is arguably the most pressing public health issue in the United States. Prevalence of obesity is extremely high, and its chronic progression is associated with type 2 diabetes and adverse cardiovascular health. Current therapies have struggled to achieve meaningful weight-loss efficacy without compromising the overall risk benefit of intervention. Following a series of high-profile market withdrawals from the 1990s onward, the obesity drug landscape became a wasteland. However, market fortunes changed and the 2012-2017 period saw a relative rush of new treatment options become available. In our Obesity Unmet Need 2017 analysis, surveyed endocrinologists reveal how the current generation of antiobesity drugs compare, and determine what attributes the next generation of drugs will need to break into the market.
- What are the treatment drivers and goals for obesity?
- What attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for obesity?
- What are the prevailing areas of unmet need and opportunity in obesity?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European endocrinologists for a hypothetical new obesity drug?
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 31 European endocrinologists fielded in November 2016
Key companies: Novo Nordisk, Vivus, Orexigen Therapeutics
Key drugs: Saxenda, Qsymia, Contrave/Mysimba